Analytical Data
-
Gene name
Lithostathine-1/Reg1
- Application
-
Alternative Names
Islet of Langerhans regenerating protein 1 Short name:REG 1 Pancreatic stone protein 1 Short name:PSP Pancreatic thread protein 1 Short name:PTP Regenerating protein 1
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43137
-
Expression Region
22-165aa
-
Molecular Weight
32.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Lithostathine-1, also known as Reg1, is a prominent member of the regenerating protein family, primarily found in the pancreas and involved in various physiological processes, including cell growth, differentiation, and regeneration. It plays a critical role in the modulation of inflammation and tissue repair, making it a subject of interest in various biomedical research areas, particularly concerning diabetes and pancreatitis. The expression of lithostathine-1/Reg1 is often upregulated in pancreatic diseases, suggesting its potential as a biomarker and therapeutic target. Research on the recombinant form of this protein has gained traction, as it allows for in-depth studies of its biological functions, structural properties, and interactions with other cellular components. By utilizing recombinant DNA technology, scientists can produce significant quantities of lithostathine-1 for analytical and experimental applications, aiding in the elucidation of its mechanisms of action. Furthermore, the recombinant protein can be employed in drug delivery systems or as a biomarker for early diagnosis, thus holding promise for advancing therapeutic strategies against pancreatic disorders. Given the increasing prevalence of pancreatic diseases globally, the exploration of lithostathine-1/Reg1 through recombinant protein studies can offer insights into new treatment modalities and improve understanding of pancreatic pathology.
